news
Head and neck cancer treatment market to reach $1.53b by 2024
3 February 2016 | By Victoria White
GlobalData says the treatment market for head and neck cancer will expand almost fourfold from $386 million in 2014 to $1.53 billion...
List view / Grid view
Drug Markets
news
Incentives and collaborations required to tackle superbugs, says GlobalData
2 February 2016 | By GlobalData
A GlobalData analyst says increased collaboration and further financial incentives are required to fight the mounting threat posed by superbugs...
news
B-cell NHL treatment market to reach $5.45 billion by 2024, says GlobalData
28 January 2016 | By Victoria White
GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline...
news
Cosentyx to achieve blockbuster status
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
news
SCLC treatment market value to rise to $2.29b by 2024, says GlobalData
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
news
Pulmonary arterial hypertension treatment market to experience modest growth
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
news
Hepatitis B therapeutics market to rise to $3b by 2024, says GlobalData
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
news
Hodgkin’s lymphoma treatment market to hit $1.4b by 2024, says GlobalData
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
news
Bladder cancer treatment market set to boom, says GlobalData
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
news
RSV treatment market to expand at ‘unprecedented levels’
13 January 2016 | By Victoria White
The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData...
news
Glioblastoma treatment market to increase to $3.3 billion
13 January 2016 | By Victoria White
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, according to research and consulting firm GlobalData...
news
Sjögren’s syndrome treatment market to grow to $2.2b by 2024
13 January 2016 | By Victoria White
GlobalData states that this impressive growth will be driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021...
news
Vasculitis treatment market to expand in value to $558m by 2024
8 January 2016 | By Victoria White
GlobalData states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis...
news
MRSA treatment market to experience limited growth, says GlobalData
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
news
Gastric cancer treatment market to reach $4.4b by 2024
4 January 2016 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration...
